Menu

Vaccine Blocks Psychostimulant Drug in Mice: Study

Scientists also show that fenethylline’s chemical constituents work together to produce its rapid, potent effects, which have been exploited by Islamic State fighters.

Aug 17, 2017
Aggie Mika

Captagon moleculeWIKIMEDIA, JYNTO In a report published today (August 16) in Nature, researchers uncover the mechanisms by which the psychoactive and addictive drug fenethylline, trade name Captagon, exerts its potent stimulating effects. Essentially, one component of the drug, theophylline, boosts the effects of another, amphetamine.

“This combination greatly enhances amphetamine’s properties,” says coauthor and Scripps Research Institute researcher Kim Janda in a press conference this week, Reuters reports. “So this now makes sense why it’s being so heavily abused.”

In exploring fenethylline’s mode of action, the researchers came upon a method to vaccinate against the drug in mice using small, antibody-eliciting molecules called haptens that target the drug’s chemical components. Once antibodies for a specific chemical are prompted by a vaccine, they bind to and prevent it from interacting with its receptors in the body, thus preventing the effects of the drug driven by that chemical.

Fenethylline’s use is mostly confined to the Middle East, where approximately 40 percent of young adult drug users in Saudi Arabia are addicted to the drug, the authors write in their report.

According to Reuters, the drug initially sparked Janda’s interest because of its use by Islamic State jihadists. According to the San Diego Union-Tribune, “Syrian civil war combatants and Islamic State terrorists have reportedly used the drug to boost their fighting ability and to lessen fear.”

Janda’s main goal was not to develop a vaccine for fenethylline, Reuters reports. Rather, he and his team used the approach of systematically blocking each drug constituent with haptens to better understand how it works. “But if there was an interest in developing it as vaccine for humans, we could do that,” he adds. 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!